δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain...

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Opioids are primary analgesics, but somatostatin (SST) also provides pain relief, even when opioids fail.
• Somatostatin receptor 4 (SSTR4) is crucial for pain modulation, as its absence in mice leads to sustained pain.
• The interaction between SSTR4 and opioid receptors in pain management is not fully understood.

Purpose of the Study:

• To investigate the physical and functional interaction between somatostatin receptor 4 (SSTR4) and the delta-opioid receptor (δOR).
• To elucidate the role of the SSTR4-δOR heteromeric complex in pain signaling and opioid withdrawal.
• To explore the potential of targeting this complex for novel pain therapeutics.

Main Methods:

• Utilized brain slices, cultured neurons, and HEK-293 cells for co-expression and interaction studies.
• Investigated heteromeric complex formation using co-immunoprecipitation and cellular imaging techniques.
• Assessed downstream signaling pathways, including cAMP/PKA and ERK1/2 activation, in response to receptor activation.

Main Results:

• Demonstrated that SSTR4 and δOR form a heteromeric complex in cortical/striatal regions and the spinal cord.
• Showed that SSTR4 and δOR co-activation synergistically inhibits cAMP/PKA signaling and opposes individual receptor-induced trafficking.
• Identified synergistic modulation of downstream pathways, with SSTR4 playing a predominant role in preventing withdrawal symptoms.

Conclusions:

• SSTR4 and δOR form a functional heteromeric complex, directly interacting within the cell membrane.
• This complex plays a key role in synergistic pain relief and preventing opioid withdrawal.
• Targeting the SSTR4-δOR interaction presents a promising therapeutic avenue for managing pain and mitigating opioid side effects.